Oncolytics Biotech Inc., the Calgary AB based company "focus[ing] on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers," recently obtained a patent regarding the prevention of reovirus recognition. U.S. Patent No. 7,014,847 ("Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders"), issued on March 21st, discloses several methods "directed to the enhancement of the effectiveness of existing reovirus therapies in the treatment of proliferative disorders." The independent claim of the patent teaches a method of treating a mammalian neoplasm by performing a step from a group of administering immune suppressive agents to neoplastic cells, removing anti-reovirus antibodies, administering anti-antireovirus antibodies, and suppressing the immune system, and then "administering to the mammal an oncolytically effective amount of reovirus; wherein the neoplasm comprises cells in which the phosphorylation of PKR is prevented." Oncolytics currently has a number of clinical trials ongoing regarding its REOLYSIN® product, which, according to its website, "has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway," and that "REOLYSIN® may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders." This is the 15th U.S. patent issued to Oncolytics.

U.S. Patent No. 7,014,847: LINK
Oncolytics Biotech Press Release: LINK
Oncolytics Biotech Website: LINK